Looking ahead in oncology

KOL Panel Discusses Cell and Gene Therapy Trends
May 19, 2021 at 12:30 PM EST

To save your spot, register here:

Join Lisa Logan and a group of oncology experts in discussing the possibilities of CAR T-cell therapy expansion to treat solid tumors as well as the implications on the current and future landscape of treatments across tumor types.

Lisa Logan
KMK Associate Principal - Market Research

You may have seen the recent news that advances in cellular engineering have now made it possible to target CAR T-cell therapy against solid tumors. This got us wondering – if CAR T-cell therapy, which is potentially curative in the liquid tumor space, proves effective in solid tumors as well, what does this mean for the targeted therapies and immuno-oncology agents which are currently dominating the treatment landscape in solid tumors?

How will treaters trade off the sky-high costs and logistical obstacles of CAR T-cell therapy with the familiarity, “simplicity” and relatively lower-priced treatments they are currently using for solid tumors? And what could mean for other emerging cell and gene therapies (i.e., TIL, TCR, NK) in the coming years?

We invite you to submit any questions that you would personally like to ask the experts – you will have the option to submit questions during registration for the session or during the live discussion via a chat feature.

KOL Panelists Announced!

Dr. Matthew Frigault

Currently serving as an Oncologist and Director of Cellular Therapy Service at Massachusetts General Hospital and Instructor of Medicine at Harvard Medical School. His research experience includes pre-clinical development and correlative studies relevant to T-cell immunotherapy as well as therapies utilizing marrow infiltrating lymphocytes and chimeric switch receptors. Dr. Frigault’s current research focuses on the translational aspects of cellular therapies with the goal of developing the next generation of cellular therapies utilizing multi-cistronic lentiviral vectors, CRISPR gene editing and clinical correlatives.

Dr. Jae Park

Attending Physician in the Division of Hematologic Oncology, Leukemia Service at Memorial Sloan Kettering Cancer Center. He is currently the lead investigator of MSKCC's Chimeric Antigen Receptor T-cell (CAR-T) therapy in ALL and CLL. Dr. Park has also written numerous peer-reviewed articles, book chapters, and editorials, and his research has been recognized and funded by the AACR, ASCO, Leukemia and Lymphoma Society, Geoffrey Beene Research Foundation, and NCCN.

Sign up to be notified about future KMK events: